Clostridioides difficile infection (CDI) is an opportunistic infection of the gastrointestinal tract, commonly associated with antibiotic administration, that afflicts almost 500 000 people yearly only in the United States. CDI incidence and recurrence is increased in inflammatory bowel disease (IBD) patients. Omilancor is an oral, once daily, first-in-class, gut-restricted, immunoregulatory therapeutic in clinical development for the treatment of IBD.
NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
Download Press Release New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ulcerative colitis and Crohn’s disease patients Omilancor and NIM-1324 reduced disease severity, pathology and...
